Xiaowei Chen obtained his Ph.D. degree from The University of North Carolina at Chapel Hill in 2002. Chen is currently an Assistant Professor and a Member of the Women’s Cancer Program and the Personalized Risk and Prevention Keystone Program at Fox Chase Cancer Center. Chen has authored or coauthored more than 15 manuscripts that have been published in top flight journals, including Molecular Cell, Cancer Research, and Human Molecular Genetics. His recent studies include the identification of the association between allelic imbalance in BRCA1 and BRCA2 gene expression and breast cancer risk. Chen has been a past recipient of the AACR-Anna D. Barker Award for basic research in 2003 and the AACR Scholar-in-Training Award in 2006, and he has been an ad hoc Member of the Breast Cancer Research Program (BCRP) Integration Panel, USAMRMC, since 2009. His research has been supported by the DOD Breast Cancer Research Program and Susan G. Komen for the Cure. The Chen laboratory has had a long-standing interest in the field of cancer risk assessment and molecular-targeted prevention, and its research has both a basic and translational focus. Current research projects include the identification of novel breast cancer susceptibility genes by evaluating genes encoding novel proteins that function in pathways integrated with BRCA1/2 or by genome-wide allele-specific expression (ASE) analysis; the development of RNAi-based breast-cancer-targeted therapy in these novel breast cancer susceptibility gene-related pathways; the identification of novel serum biomarkers for breast cancer early detection. The research goal of Chen is to identify differences among normal, premalignant, and cancerous breast tissue, determine their consequences, and use this information to improve the patient care.
Biography Updated on 1 December 2011